Navigation Links
amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
Date:2/22/2008

More Than 100 Groups Apply for Grants to Assist Men Who Have Sex With Men in Developing Countries

NEW YORK, Feb. 21 /PRNewswire-USNewswire/ -- In an ambitious move to significantly bolster global HIV program efforts targeting populations especially vulnerable to HIV, amfAR, The Foundation for AIDS Research, has announced the first recipients of funding given out under its new MSM Initiative. These community awards will fund 17 grassroots and frontline organizations in Africa, the Caribbean and Southeast Asia that are working to provide essential HIV/AIDS prevention, care and support services for men who have sex with men (MSM), amfAR CEO Kevin Robert Frost announced today.

"MSM are one of the populations worst affected by HIV worldwide, and this is the first global initiative of its kind supporting local organizations working to address HIV among MSM in developing countries," Frost said.

According to UNAIDS, fewer than one in 20 MSM around the world have access to appropriate HIV/AIDS services. Stigma, discrimination, and lack of access to health services have sparked alarming epidemics that threaten the lives of MSM in underdeveloped regions, mirroring the HIV epidemics that ravaged gay men in North America and Western Europe in the 1980s.

"The MSM Initiative is working to galvanize a much needed global response to the enormous gaps in funding and services for MSM at risk of HIV/AIDS through a partnership with amfAR, UNAIDS, and the Global Forum on MSM and HIV," said Dr. Peter Piot, Executive Director of the Joint United Nations Programme on HIV/AIDS (UNAIDS). "Leadership in the gay community was instrumental in the response to the HIV/AIDS epidemic in the West. This initiative is fostering new leadership and support for this issue in developing countries across the globe, including nations where male-male sex is illegal and often heavily stigmatized."

These awards mark the first funding cycle completed by t
'/>"/>

SOURCE amfAR, The Foundation for AIDS Research
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
2. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
3. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
4. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
5. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
6. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
7. Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
10. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
11. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...e-FirstCall/ -- GeoVax Labs, Inc.,(OTC Bulletin B...y developing,human vaccines for diseases caused b...infectious agents, announced today that the launch...lace in twelve sites across North and South Americ...th The National Institutes of,Health (NIH), and t...
(Date:11/28/2008)...ewswire-FirstCall/ -- Eli Lilly and Company,(NYSE...Application (sNDA) from,the U.S. Food and Drug Ad...),for the management of chronic pain. Lilly plans... 2009, adding data from a recently completed posit...nee. , The decision does not affect duloxet...
(Date:11/25/2008)...ove recovery , , Audio and Web Video Resour...ayo Clinic News Blog. Please see the bottom of thi...Minn., Nov. 25 A Mayo C...n,t think they,re having a stroke -- and as a resu...n worsens. The findings appear in the current issu...
(Date:11/25/2008)... Pharmacyclics, Inc.,(N...as completed a Phase 1,clinical trial with PCI-27...lecule Factor VIIa inhibitor. The trial was conduc...e the safety and pharmacologic effect of,PCI-2748...n a linear dose,response in the International Nor...
Breaking Medicine Technology:GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Research Attributes Lack of HIV AIDS Vaccine to Use of Chimpanzees 3225 1Research Attributes Lack of HIV AIDS Vaccine to Use of Chimpanzees 3225 2Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer 5246 1Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer 5246 2Surface tension drives segregation within cell mixtures 5244 1Surface tension drives segregation within cell mixtures 5244 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3223 1Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3223 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3223 3
...ase 1 Colorectal and Prostate Cancer,Trials To Be ...RANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCa...ceutical company,focused on oncology, today announ...the Company,s lead product candidate, in patients,...ed in a poster,session at the 43rd Annual Meeting ...
...07 /PRNewswire-FirstCall/ -- Vical,Incorporated to...study, a DNA vaccine formulated with the company,s...needle-free injection,yielded significantly higher...ne delivered by needle and syringe. In a,separate ...of,unformulated vaccine yielded comparable improve...
Other Medicine Technology:Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 2Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 3Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 4Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 2Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 3Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 4
(Date:12/2/2008)...a leading provider of onsite health services and t...e, the athletic products company, has selected Mar...te health clinics and to provide health services t... Burlington, VT (PRWEB) Decem... of onsite employee health services and technology...
(Date:12/2/2008)...nal Day of Disabled Persons is recognized on Dec. ...g boy born with backwards pointing feet. After fre...ospital docked in Liberia, Benedict,s feet are cor...children his age. High resolution photos and vid...g , Garden Valley, TX (V...
(Date:12/2/2008)...unces that the SouthEast Alaska Regional Health Co...the Rhapsody™ Integration Engine to help the...armacy, laboratory and business programs communica...tivity to statewide systems such as VacTrAK (the S...an MIS and clinical documentation tool used by sub...
(Date:12/2/2008)...orola, Inc. (NYSE: MOT ),announced today that i...enable,three hospitals managed by leading Europea...to deliver voice, data and video services. The inn... broadband infrastructure to support,multimedia s..., eliminating,the need for additional cabling or ...
Breaking Medicine News(10 mins):Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Mercy Ships Recognizes International Day of Disabled Persons 2Health News:Mercy Ships Recognizes International Day of Disabled Persons 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Motorola Extends the Delivery of Personalized Media Experiences to Hospital Group Generale De Sante 2Health News:Motorola Extends the Delivery of Personalized Media Experiences to Hospital Group Generale De Sante 3
...al cardiologist at the Washington Hospital Center ...ergy) to restore blood flow in blocked arteries. /...eople suffering from advanced diabetes as it leads...ns such as amputation. People with diabetes and e...
...s of Kryptiq's Care Manager Diabetes Module at the...ems Society (HIMSS) conference. // This module ...nts who benefited. The one year study showed that ...holesterol and blood pressure levels. Providence M...
...y men contact in Hong Kong has been in a way respo... a latest report. // Government health officials ...vember 2005, had HIV with similar gene sequencing,...st reported. The discovery was made when all the ...
...d be as simple as swallowing a spongy pill with a ...ts of Cambridge University researchers // that can... UK every year. It is the ninth most commonly occu...he windpipe, the pill is pulled out, gently scrapi...
Other Medicine News:Health News:Laser Used To Clear Blocked Arteries Preventing Amputation, 2Health News:Kryptiq Care Manager Diabetes Module Effective In Managing Diabetes 2
Gold Labeling kit for antibodies, the Coat-Block-Run Conjugation Kit pH 5-8; contains 1 bottle each of 20 nm and 40 nm Naked Gold
Colloidal Gold Conjugated, Goat anti-mouse IgG (H&L) - 12 OD
Colloidal Gold Conjugated, Goat anti-mouse IgG (H&L) - 50 OD
Colloidal Gold Conjugated, Goat anti-human IgM (Mu Chain) - 12 OD
Medicine Products: